350 related articles for article (PubMed ID: 9307181)
1. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies.
van Noesel MM; Hählen K; Hakvoort-Cammel FG; Egeler RM
Cancer; 1997 Sep; 80(5):834-43. PubMed ID: 9307181
[TBL] [Abstract][Full Text] [Related]
2. [Hepatopathy in patients with stage 4S neuroblastoma].
Claviez A; Hero B; Schneppenheim R; Berthold F
Klin Padiatr; 1996; 208(4):221-8. PubMed ID: 8926687
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic large cell neuroblastoma.
Abramowsky CR; Katzenstein HM; Alvarado CS; Shehata BM
Pediatr Dev Pathol; 2009; 12(1):1-5. PubMed ID: 18397155
[TBL] [Abstract][Full Text] [Related]
4. Is aggressive local treatment necessary for diffuse liver involvement in patients with progression of stage 4s neuroblastoma to stage 4?
Heij HA; Verschuur AC; Kaspers GJ; van Rijn RR; Adam JA; Aronson DC
J Pediatr Surg; 2008 Sep; 43(9):1630-5. PubMed ID: 18778997
[TBL] [Abstract][Full Text] [Related]
5. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
6. Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
Pediatr Blood Cancer; 2006 Mar; 46(3):278-84. PubMed ID: 16124002
[TBL] [Abstract][Full Text] [Related]
7. [4S neuroblastoma with bilateral adrenal tumors].
Kerdudo C; Corradini N; Michon J; Leverger G
Arch Pediatr; 2004 Dec; 11(12):1450-6. PubMed ID: 15596333
[TBL] [Abstract][Full Text] [Related]
8. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate.
Hsu LL; Evans AE; D'Angio GJ
Med Pediatr Oncol; 1996 Dec; 27(6):521-8. PubMed ID: 8888811
[TBL] [Abstract][Full Text] [Related]
9. The role of bone marrow evaluation in the staging of patients with otherwise localized, low-risk neuroblastoma.
Russell HV; Golding LA; Suell MN; Nuchtern JG; Strother DR
Pediatr Blood Cancer; 2005 Dec; 45(7):916-9. PubMed ID: 16078212
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
11. Neuroblastoma in adolescents.
Gaspar N; Hartmann O; Munzer C; Bergeron C; Millot F; Cousin-Lafay L; Babin-Boilletot A; Blouin P; Pajot C; Coze C
Cancer; 2003 Jul; 98(2):349-55. PubMed ID: 12872356
[TBL] [Abstract][Full Text] [Related]
12. A sequential treatment algorithm for infants with stage 4s neuroblastoma and massive hepatomegaly.
Weintraub M; Waldman E; Koplewitz B; Bloom AI; Gross E; Freeman AI; Revel-Vilk S
Pediatr Blood Cancer; 2012 Jul; 59(1):182-4. PubMed ID: 22605456
[TBL] [Abstract][Full Text] [Related]
13. Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification.
Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Nagasaki A; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Eguchi H; Tsuneyoshi M
J Pediatr Surg; 2000 Dec; 35(12):1737-41. PubMed ID: 11101726
[TBL] [Abstract][Full Text] [Related]
14. [Neuroblastoma IV-S. A multicenter study. Work Group of Pediatric Oncology. Spanish Society of Pediatric Surgery].
Rollán Villamarín V; García Aroca J; Costa Borrás E; Cuadros García J; Jiménez Alvarez C; Martínez-Caro A; Martínez Ibáñez V; Mulet Ferragut F; Obiols Arderius P; Pérez La Fuente G
Cir Pediatr; 1994 Oct; 7(4):167-70. PubMed ID: 7865360
[TBL] [Abstract][Full Text] [Related]
15. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
16. [Management strategy in neuroblastoma].
Balwierz W
Przegl Lek; 2004; 61 Suppl 2():3-8. PubMed ID: 15686038
[TBL] [Abstract][Full Text] [Related]
17. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
[TBL] [Abstract][Full Text] [Related]
19. [Neuroblastoma: biological markers, surgery, and clinical course].
Martínez Ibáñez V; Abad P; Gallego S; Sánchez de Toledo J; Marqués A; Boix Ochoa J
Cir Pediatr; 2000 Apr; 13(2):47-53. PubMed ID: 12602001
[TBL] [Abstract][Full Text] [Related]
20. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
George RE; Kenyon RM; McGuckin AG; Malcolm AJ; Pearson AD; Lunec J
Oncogene; 1996 Apr; 12(7):1583-7. PubMed ID: 8622876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
